Use of phytoestrogen to counter femininity issues caused by estrogen deficiency such as vaginal dryness, thin vaginal wall, healthy vaginal pH, and other vaginal and vulvar atrophic symptoms, has been suggested by nutritionists, herbal practitioner, and even doctors either through dietary intervention or certain herbal therapies containing phytoestrogens. That being said, it is not only beneficial against vaginal dryness, but can also restore vaginal tightness and improve its health.
In medicine, use of estradiol therapy with lower dose is a best practice to prevent potential harmful risks that may come with when used for quite long. This therapy is commonly offered by doctor for menopausal and postmenopausal to overcome vaginal atrophy which is caused by estrogen deficiency. Vaginal atrophy is a thinning vaginal walls and dryness causing various uncomfortable sensation, such as painful sex, itching, burning sensation, as well as at higher risk of bacterial infections.
However, since low doses synthetic estrogen may also associated with the risk of cardiovascular events and cancer onset, therefore, most doctors recommend it for short-term therapy.
Now one of pharmaceutical companies claims they have made a new estradiol drugs that probably safe, especially in lower dose, to overcome vaginal and vulva atrophy. Since it's a new formula, therefore, they cannot ensure the safety profile for long-term use.
According to their news release, their trial showed it can increase the thickness of vaginal wall, overcome vaginal dryness, and friendly pH level. The synthetic estrogen is a solubilized 17 beta-estradiol developed by TherapeutisMD in Boca Raton, Florida. The trial results presented on April 2, 2016, at the annual meeting of the Endocrine Society, in Boston.
The trial enrolled 764 postmenopausal women in double-blind at 105 medical centers in the U.S and Canada. Participants were 40 through 75 years of age and their most bothersome symptom was moderate-to-severe dyspareunia (painful intercourse).
Overall, the researchers said that within two weeks, at all treatment drug doses, vaginal cells and vaginal pH significantly improved, compared with placebo. (ref)
At week 2, 6 and 8, the vaginal pH and percentage of parabasal cells significantly decreased, the percentage of superficial cells significantly increase (thickness of vaginal wall), and the dyspareunia severity significantly diminished from baseline with doses of 4 mcg, 10 mgc, and 25 mcg, compared with placebo.
Moderate-to-severe vaginal dryness, reported by 93% of participants at baseline, significantly improved for all doses at weeks 2, 6, 8, and 12, except for 4 mcg at week 12. Vulvar and/or vaginal itching or irritation significantly diminished for 10 mcg at weeks 8 and 12, and for 25 mcg at week 12.
At week 12, all doses significantly reduced the vaginal pH and percentage of parabasal cells, significantly increased the percentage of superficial cells, and significantly diminished dyspareunia severity, compared with placebo.
As synthetic estrogen therapy often causes cardiovascular events, they claim their formula did not elevate blood estradiol higher than normal postmenopausal range.
The maker of this estradiol drug plans to use the results of this study in its new drug application to the FDA for approval.
After all, imagine the estrogenic activities obtained from oral estradiol can rejuvenate vaginal walls and its health... what if that 'external estrogenic activities' are directly given to targeted areas such as through topical administration that contains strong phytoestrogens profile derived from Oak Gall, Witch Hazel, P. Mirifica and other potent herbs? Does it more powerful and safe to rejuvenate your genital organs and its health? Surely you know the answer. Read this page for more detail.
To bookmark this page, press (Ctrl+D) for Firefox and IE, press (Ctrl+T) for Opera, or press (Command+D) for Macs